中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Trilaciclib Granted Fast Track Designation by the U.S. FDA for Use in Combination with Chemotherapy for the Treatment of TNBC

On 19 June 2021, the U.S. Food and Drug Administration has granted Trilaciclib (COSELATM) the Fast Track Designation for use in combination with chemo...

2021-07-30
Phase Ⅱ Clinical Data of Envafolimab in MSI-H/dMMR Solid Tumors Published in the Journal of Hematology & Oncolog

On June 21st, 2021, the data of a Phase Ⅱ clinical study on Envafolimab as monotherapy in treating patients with advanced MSI-H/dMMR solid t...

2021-07-21
Envafolimab Obtained Its 2nd Orphan Drug Designation from the U.S. Food and Drug Administration

On 29 June 2021, Simcere announced that the innovative subcutaneously injected PD-L1 single domain antibody Envafolimab has received the Orphan ...

2021-06-30
Simcere and Vivoryon Therapeutics Announce Strategic Regional Licensing Partnership for N3pE Amyloid-Targeting Medicines to Treat Alzheimer’s Disease in Greater China

Simcere Pharmaceutical Group Limited (HKEX: 2096), a pharmaceutical company rapidly transitioning to an innovative and R&D-driven company in Chi...

2021-06-29
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.